TTP 054

Drug Profile

TTP 054

Alternative Names: TTP054

Latest Information Update: 18 Aug 2015

Price : $50

At a glance

  • Originator TransTech Pharma
  • Developer vTv Therapeutics
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 18 Aug 2015 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
  • 25 Jun 2013 Safety, pharmacokinetics and pharmacodynamics data from a phase I trial in Type 2 diabetes mellitus released by TransTech Pharma
  • 31 May 2013 TransTech Pharma completes a phase II trial in Type-2 diabetes mellitus in USA (NCT01665352)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top